Track topics on Twitter Track topics that are important to you
New data from late-stage trials suggests that Pfizer’s dacomitinib beat out AstraZeneca’s rival treatment Iressa (gefitinib) at halting the progression of EGFR-positive non-small cell lung cancer (NSCLC), albeit with a higher prevalence of side-effects.
Like older treatments, dacomitinib targets abnormal epidermal growth factor receptor genes in advanced lung cancer. In a study of 452 patients, Pfizer’s drug exhibited the ability to delay the progression of cancer for 14.7 months, compared to 9.2 months for AZ’s Ingressa – a 41% improvement.
Original Article: Pfizer drug beats AZ rival in halting lung cancerNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...